Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01309087 · ClinicalTrials.gov registry record

Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: AEGIS CLIA

A clinical trial of Lung Cancer, sponsored by Allegro Diagnostics.

Completed
Registry status
756
Enrollment target
14
Study locations

NCT01309087: Completed study of Lung Cancer, sponsored by Allegro Diagnostics.

NCT01309087 is a study of Lung Cancer that has completed, run by Allegro Diagnostics. The registered enrollment target is 756 participants, below the 934-participant average among 409 other Lung Cancer trials with a reported enrollment target (19% lower). The trial reports 14 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist → Add completion date to calendar (.ics) →

The verdict

NCT01309087, a study of Lung Cancer, has completed, sponsored by Allegro Diagnostics.

COMPLETED
Registry status
756 participants
Enrollment target
14
Study locations

Study Summary

The primary objective of this study is to substantiate prediction accuracy(with a tighter 95% confidence interval compared to current diagnostic modalities), of a lung cancer biomarker for risk stratification of patients into high and low risk categories to aid in clinical evaluation of the patient.

Conditions Studied

Study Locations (14)

New York

  • New York University - New York
  • Columbia University - New York

Pennsylvania

  • University of Pennsylvania - Philadelphia
  • Temple University - Philadelphia

Alabama

  • University of Alabama - Birmingham

Georgia

  • Georgia Lung Associates - Austell

Indiana

  • Indiana University - Indianapolis

Louisiana

  • LSU - New Orleans

Massachusetts

  • Beth Israel Deaconess Medical Center - Boston

Missouri

  • University of Missouri - Columbia

Trial Details

FieldValue
Enrollment Target 756 participants
Start Date 2009-01
Est. Completion 2013-05
Allegro Diagnostics

2 total trials

What the finished NCT01309087 record still lists

NCT01309087 is an observational study that tracks outcomes without assigning an intervention. The registered 756 participants enrollment target is mid-sized for trials with a published cap, below the 934-participant average among 409 other Lung Cancer trials with a reported enrollment target (19% lower).

The record links to 1 condition, with Lung Cancer appearing as the primary indexed condition, and to 0 interventions.

NCT01309087 lists 14 locations in 12 states (New York, Pennsylvania, Alabama).

Frequently Asked Questions

What is clinical trial NCT01309087 about?

NCT01309087 is a clinical study titled "Airway Epithelium Gene Expression in the Diagnosis of Lung Cancer: AEGIS CLIA". The primary objective of this study is to substantiate prediction accuracy(with a tighter 95% confidence interval compared to current diagnostic modalities), of a lung cancer biomarker for risk stratification of patients into high and low risk categories to aid in clinical evaluation of the patient.

What is the current status of trial NCT01309087?

This trial is currently completed. The enrollment target is 756 participants. The study started on 2009-01. Estimated completion is 2013-05.

What conditions does trial NCT01309087 study?

This clinical trial studies the following conditions: Lung Cancer.

Who is sponsoring clinical trial NCT01309087?

This trial is sponsored by Allegro Diagnostics, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01309087 being conducted?

This trial has 14 study locations across Alabama, Georgia, Indiana, Louisiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Lung Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01309087's enrollment target sits among peer trials

756 57th of 409 higher than 353 of 409 other Lung Cancer trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT05869149 · 756 participants · NA

    Systems Science Approaches to Improve Access to Healthier Foods: The FRESH Trial

  • NCT06095583 · 756 participants · Phase 3

    Phase 3 Study of Toripalimab Alone or in Combination With Tifcemalimab as Consolidation Therapy in Patients With Limited-stage Small Cell Lung Cancer (LS-SCLC)

  • NCT05379985 · 754 participants · Phase 1

    Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS

  • NCT05427370 · 754 participants · NA

    The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01309087, the US trial registry maintained by the National Library of Medicine. NCT01309087 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.